Mackenzie Financial’s Cytek Biosciences CTKB Stock Holding History

Mackenzie Financial’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.82M	Buy	+305,136	New	+$1.45M	﹤0.01%	1064

Other funds holding CTKB

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Mackenzie Financial's CTKB Position: Q3 2026 in Review

Mackenzie Financial opened a new position in Cytek Biosciences (CTKB) in Q3 2026: 305,136 shares worth $1.82M. The stake represents ﹤0.01% of the portfolio and ranks #1064 among its holdings.

29 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

Mackenzie Financial held 305,136 shares of Cytek Biosciences worth $1.82M as of Q3 2026.
Cytek Biosciences was a new Mackenzie Financial position in Q3 2026.
Cytek Biosciences made up ﹤0.01% of Mackenzie Financial's portfolio in Q3 2026, its #1064 holding.
29 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Mackenzie Financial's 13F filing for Q3 2026, filed 2 Nov 2026.